CRISPR Screen Dataset
Thummuri D (2022) - 2-PMID34667112
Title: Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-X-Specific Degrader DT2216.
Screen Details:
- Screen Rationale : Increased drug resistance
- Cell Type : Pancreatic Adenocarcinoma Cell Line [BTO:0001521]
- Cell Line : AsPC-1 [BTO:0001864, CELLOSAURUS:CVCL_0152]
- Phenotype : Response To Chemicals
- Condition : Gemcitabine (3.2 μmol/L) [ChEBI]
- Library : RxG library | Type: CRISPRn | Format: Pool | Enzyme: Cas9 | Methodology: Knockout
- Analysis Method : MaGeCK | Number of Hits: 4 | Full Dataset Size: 996
- Experimental Setup : Drug Exposure | Duration: 16 Days | MOI: = 0.4
- Significance : Authors have indicated that results with Score.3 (FDR) < 0.1 are to be considered significant. These results are indicated by '' in the HIT column of the table below.
Notes:
- KO of hit gene results in increased resistance to gemcitabine
Score Distribution
< 0.99998
> 0.00000085